Neutrophil-to-lymphocyte Ratio as a Risk Determinant of Hemorrhage Transformation in Acute Ischemic Stroke

Supplementary Files

Supplementary File


Acute ischemic stroke
Hemorrhage transformation
Neutrophil-to-lymphocyte ratios




Objective: The purpose of this study was to investigate the clinical significance between neutrophil-to-lymphocyte ratio (NLR) and classification of non-thrombolytic hemorrhagic transformation (HT) in acute ischemic stroke (AIS), to unravel new diagnostic approach.

Methods: We recruited and selected 636 patients who did not undergo thrombolytic therapy between May 2018 and April 2019 at the Affiliated Hospital of Xuzhou Medical University. The laboratory and clinical data were collected within 24 h after the onset of AIS. Based on the status of HT development during hospitalization, all participants were divided into three groups, namely, the non-HT (NHT) group, hemorrhagic infarction (HI) group, and parenchymal hematoma (PH) group.

Results: Multivariate logistic regression analysis showed that NLR and the ischemic lesion diameter are independent risk factors of HI and PH, while the score of National Institutes of Health Stroke Scale (NIHSS) and cardioembolism are considered to be independent risk factors for PH only. Receiver operating characteristic (ROC) analysis determined that the optimal cutoff values of NLR in HI group and PH group were 3.75 and 3.97, respectively. The optimal cutoff value can be used as the critical value for the unfavorable outcome.

Conclusion: NLR values were significantly increased and correlated with both HI and PH groups and NLR could be used as a predictor of both HI and PH.


Yaghi, S.; Boehme, A.K.; Dibu, J.; Guerrero, C.R.L.; Ali, S.; Martin-Schild, S.; Sands, K.A.; Noorian, A.R.; Blum, C.A.; Chaudhary, S.; Schwamm, L.H.; Liebeskind, D.S.; Marshall, R.S.; Willey, J.Z. Treatment and Outcome of Thrombolysis-Related Hemorrhage: A Multicenter Retrospective Study. JAMA Neurol., 2015, 72(12), 1451-7.

Hacke, W.; Kaste, M.; Fieschi, C.; Toni, D.; Lesaffre, E.; von Kummer, R.; Boysen, G.; Bluhmki, E.; Höxter, G.; Mahagne, M.H. Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. Eur. Coop. Acute Stroke Study JAMA, 1995, 274(13), 1017-25.

Alvarez-Sabin, J.; Maisterra, O.; Santamarina, E.; Kase, C.S. Factors Influencing Haemorrhagic Transformation in Ischaemic Stroke. Lancet Neurol., 2013, 12(7), 689-705.

Jickling, G.C.; Liu, D.; Stamova, B.; Ander, B.P.; Zhan, X.; Lu, A.; Sharp, F.R. Hemorrhagic Transformation after Ischemic Stroke in Animals and Humans. J. Cereb. Blood Flow Metab., 2014, 34(2), 185-99.

Lu, G.; He, Q.; Shen, Y.; Cao, F. Potential biomarkers for predicting hemorrhagic transformation of ischemic stroke. Int. J. Neurosci., 2018, 128(1), 79-89.

Tokgoz, S.; Keskin, S.; Kayrak, M.; Seyithanoglu, A.; Ogmegul, A. Is neutrophil/lymphocyte ratio predict to short-term mortality in acute cerebral infarct independently from infarct volume? J. Stroke Cerebrovasc. Dis., 2014, 23, 2163-8.

Duan, Z.; Wang, H.; Wang, Z.; Hao, Y.; Zi, W.; Yang, D.; Zhou, Z.; Liu, W.; Lin, M.; Shi, Z.; Lv, P.; Wan, Y.; Xu, G.; Xiong, Y.; Zhu, W.; Liu, X. Neutrophil-Lymphocyte Ratio Predicts Functional and Safety Outcomes after Endovascular Treatment for Acute Ischemic Stroke. Cerebrovasc. Dis. 2018, 45(5-6), 221-7.

Afari, M.E.; Bhat, T. Neutrophil to Lymphocyte Ratio (NLR) and Cardiovascular Diseases: An Update. Expert. Rev. Cardiovasc. Ther., 2016, 14(5), 573-7.

Celikbilek, A.; Ismailogullari, S.; Zararsiz, G. Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Ischemic Cerebrovascular Disease. J. Clin. Lab. Anal., 2014, 28(1), 27-31.

Li, M.X.; Liu, X.M.; Zhang. X.F.; Wang, W.L.; Zhu, Y.; Dong, J.; Cheng, J.W.; Liu, Z.W.; Ma, L.; Lv, Y. Prognostic Role of Neutrophil-to-lymphocyte Ratio in Colorectal Cancer: A Systematic Review and Meta-analysis. Int. J. Cancer, 2014, 134(10), 2403-13.

de Jager, C.P.; van Wijk, P.T.; Mathoera, R.B.; de Jongh- Leuvenink, J.; van der Poll, T.; Wever, P.C. Lymphocytopenia and Neutrophil-lymphocyte Count Ratio Predict Bacteremia better than Conventional Infection Markers in an Emergency Care Unit. Crit Care, 2010, 14(5), R192.

Kim, J.H.; Lim, S.; Park, K.S.; Jang, H.C.; Choi, S.H. Total and Differential WBC Counts are Related with Coronary Artery Atherosclerosis and Increase the Risk for Cardiovascular Disease in Koreans. PLoS One. 2017, 12(7), e0180332.

Shah, A.D.; Denaxas, S.; Nicholas, O.; Hingorani, A.D.; Hemingway, H. Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study. J. Am. Coll. Cardiol., 2017, 169(9), 1160-9.

Mazza, M.G.; Lucchi, S.; Rossetti, A.; Clerici. M. Neutrophil-lymphocyte Ratio, Monocyte-lymphocyte Ratio and Platelet-lymphocyte Ratio in Non-affective Psychosis: A Meta-analysis and Systematic Review. World J. Biol. Psychiatry, 2019, 1, 1-13.

Park, C.S. Inflammation in Cardiovascular Disease. Korean Circ. J., 2017, 47(5), 314-5.

Aurelian, S.V.; Adrian, M.; Andercou, O.; Bruno, S.; Alexandru, O.; Catalin, T.; Dan, B. Neutrophil-to-Lymphocyte Ratio: A Comparative Study of Rupture to Nonruptured Infrarenal Abdominal Aortic Aneurysm. Ann. Vasc. Surg. 2019, 58, 270-5.

Lin, L.; Piao, M.; Jiang, X.; Houning, L.V.; Zhao, N., Yang, F., Sun, C. Does Neutrophil-to-lymphocyte Ratio Predict 1-year Mortality in Patients with Primary Biliary Cholangitis? Results from a Retrospective Study with Validation Cohort. BMJ Open, 2017, 7(7), e015304.

Kikuchi, K.; Tanaka, E.; Murai, Y.; Tancharoen, S. Clinical Trials in Acute Ischemic Stroke. CNS Drugs, 2014, 28, 929-38.

Furie, K.L.; Jayaraman, M.V. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke, 2018, 49(3), 509-10.

Adams, H.P. Jr.; Biller, J. Classification of Subtypes of Ischemic Stroke: History of the Trial of org 10172 in Acute Stroke Treatment Classification. Stroke, 2015, 46(5), e114-7.

Muchada, M.; Rubiera, M.; Rodriguez-Luna, D.; Pagola, J.; Flores, A.; Kallasm, J.; Sanjuan, E.; Meler, P.; Alvarez-Sabin, J.; Ribo, M.; Molina, C.A. Baseline National Institutes of Health Stroke Scale-adjusted Time Window for Intravenous Tissue-type Plasminogen Activator in Acute Ischemic Stroke. Stroke, 2014, 45(4), 1059-63.

Nemeth, T.; Mocsai, A.; Lowell, C.A. Neutrophils in Animal Models of Autoimmune Disease. Semin. Immunol., 2016, 28(2), 174-86.

Jickling, G.C.; Liu, D.; Ander, B.P.; Stamova, B.; Zhan, X.; Sharp, F.R. Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies. J. Cereb. Blood Flow Metab., 2015, 35(6), 888-901.

Benakis, C., Garcia-Bonilla, L., Iadecola, C., Anrather, J. The Role of Microglia and Myeloid Immune Cells in Acute Cerebral Ischemia. Front Cell. Neurosci., 2014, 8, 461.

Cai, Z., Zhao, B., Deng, Y., Shangguan S1, Zhou F1, Zhou W1, Li X1, Li Y2, Chen G1. Notch Signaling in Cerebrovascular Diseases (Review). Mol Med Rep., 2016, 14(4), 2883-98.

Garcia-Culebras, A.; Duran-Laforet, V.; Pena-Martinez, C.; Ballesteros, I.; Pradillo, J.M.; Díaz-Guzmán, J.; Lizasoain, I.; Moro, M.A. Myeloid Cells as Therapeutic Targets in Neuroinflammation after Stroke: Specific Roles of Neutrophils and Neutrophil-platelet Interactions. J. Cereb. Blood Flow Metab., 2018, 38(12), 2150-64.

Ho, W.M.; Reis, C.; Akyol, O.; Applegate, R.; Stier, G.; Martin, R.; Zhang, J.H. Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation. Curr. Drug Targets, 2017, 18(12), 1441-59.

Rosenberg, G.A.; Yang, Y. Vasogenic Edema Due to tight Junction Disruption by Matrix Metalloproteinases in Cerebral Ischemia. Neurosurg. Focus, 2007, 22(5), E4.

Rosell, A.; Cuadrado, E.; Ortega-Aznar, A.; Hernandez-Guillamon, M.; Lo, E.H.; Montaner, J. MMP-9-Positive Neutrophil Infiltration is Associated to Blood-brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation after Human Ischemic Stroke. Stroke, 2008, 39(4), 1121-6.

De Meyer, S.F.; Suidan, G.L.; Fuchs, T.A.; Monestier, M.; Wagner, D.D. Extracellular Chromatin is an Important Mediator of Ischemic Stroke in Mice. Arterioscler. Thromb. Vasc. Biol., 2012, 32(8), 1884-91.

Savchenko, A.S.; Borissoff, J.I.; Martinod, K.; De Meyer, S.F.; Gallant, M.; Erpenbeck, L.; Brill, A.; Wang, Y.; Wagner, D.D. VWF-mediated Leukocyte Recruitment with Chromatin Decondensation by PAD4 Increases Myocardial Ischemia/Reperfusion Injury in mice. Blood, 2014, 123(1), 141-8.

Huang, H.; Tohme, S.; Al-Khafaji, A.B.; Damage-associated Molecular Pattern-activated Neutrophil Extracellular Trap Exacerbates Sterile Inflammatory Liver Injury. Hepatology, 2015, 62(2), 600-14.

Woiciechowsky, C.; Asadullah, K.; Nestler, D.; Eberhardt, B.; Platzer, C.; Schöning, B.; Glöckner, F.; Lanksch, W.R.; Volk, H.D.; Döcke, W.D. Sympathetic Activation Triggers Systemic Interleukin-10 Release in Immunodepression Induced by Brain Injury. Nat. Med., 1998, 4(7), 808-13.

Liesz, A.; Zhou, W.; Na, S.Y.; Boosting Regulatory T Cells Limits Neuroinflammation in Permanent Cortical Stroke. J. Neurosci., 2013, 33(44), 17350-62.

Ren, X.; Akiyoshi, K.; Dziennis, S.; Vandenbark, A.A.; Herson, P.S.; Hurn, P.D.; Offner, H. Regulatory B Cells Limit CNS Inflammation and Neurologic Deficits in Murine Experimental Stroke. J. Neurosci., 2011, 31(23), 8556-63.

Liesz, A.; Hu, X.; Kleinschnitz, C.; Offner, H. Functional Role of Regulatory Lymphocytes in Stroke: Facts and Controversies. Stroke, 2015, 46(5), 1422-30.

Kim, J.Y.; Kawabori, M.; Yenari, M.A. Innate Inflammatory Responses in Stroke: Mechanisms and Potential Therapeutic Targets. Curr. Med. Chem., 2014, 21(18), 2076-97.

Song, Q.; Li, Y.; Wang, Y.; Weim, C.; Liu, J.; Liu, M. Increased Neutrophil-to-lymphocyte Ratios are Associated with Greater Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke. Curr. Neurovasc. Res., 2018, 15(4), 326-35.

Guo, Z.; Yu, S.; Xiao, L.; Dynamic Change of Neutrophil to Lymphocyte Ratio and Hemorrhagic Transformation after Thrombolysis in Stroke. J. Neuroinflammation, 2016, 13(1), 199.

Wu, Y.; Chen, Y.; Yang, X.; Chen, L.; Yang, Y. Neutrophil-to- Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) were Associated with Disease Activity in Patients with Systemic Lupus Erythematosus. Int. Immunopharmacol., 2016, 36, 94-9.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.